Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads
暂无分享,去创建一个
Chris Bailey-Kellogg | Yoonjoo Choi | Regina S. Salvat | C. Bailey-Kellogg | K. Griswold | Yoonjoo Choi | Regina S. Salvat | Alexandra Bishop | Karl E. Griswold | A. Bishop
[1] Ronit Mazor,et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.
[2] Bruce Tidor,et al. Progress in computational protein design. , 2007, Current opinion in biotechnology.
[3] Chris Bailey-Kellogg,et al. Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.
[4] Bjoern Peters,et al. Evaluating the Immunogenicity of Protein Drugs by Applying In Vitro MHC Binding Data and the Immune Epitope Database and Analysis Resource , 2013, Clinical & developmental immunology.
[5] Wolfgang Aehle,et al. A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.
[6] Chris Bailey-Kellogg,et al. A divide‐and‐conquer approach to determine the Pareto frontier for optimization of protein engineering experiments , 2012, Proteins.
[7] Leonard Moise,et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.
[8] Maria D. F. S. Barbosa,et al. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. , 2011, Drug discovery today.
[9] L. Holm,et al. The Pfam protein families database , 2005, Nucleic Acids Res..
[10] Morten Nielsen,et al. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.
[11] J. Cizeau,et al. Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin , 2009, Journal of immunotherapy.
[12] A. Jevnikar,et al. The relationship between predicted peptide–MHC class II affinity and T-cell activation in a HLA-DRβ1*0401 transgenic mouse model , 2002, Arthritis research & therapy.
[13] David Baker,et al. Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.
[14] Fiona Adair,et al. The immunogenicity of therapeutic proteins , 2002 .
[15] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[16] Ira Mellman,et al. Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.
[17] Saurabh Aggarwal,et al. What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.
[18] Chris Bailey-Kellogg,et al. A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. , 2014, Journal of visualized experiments : JoVE.
[19] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[20] Chris Bailey-Kellogg,et al. Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..
[21] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[22] Morten Nielsen,et al. MHC Class II epitope predictive algorithms , 2010, Immunology.
[23] Chris Bailey-Kellogg,et al. Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate , 2015, PLoS Comput. Biol..
[24] Amy C. Anderson,et al. Computational structure-based redesign of enzyme activity , 2009, Proceedings of the National Academy of Sciences.
[25] John Sidney,et al. The HLA Molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 Share an Extensive Overlap in Peptide Binding Specificity1 , 2002, The Journal of Immunology.
[26] William W. Kwok,et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.
[27] Marcia Stickler,et al. Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope , 2004, The Journal of Immunology.
[28] Chris Bailey-Kellogg,et al. Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate , 2014, Cellular and Molecular Life Sciences.
[29] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[30] Christine J. Bryson,et al. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.
[31] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[32] Tim D. Jones,et al. Prediction of Immunogenicity of Therapeutic Proteins , 2010, BioDrugs.
[33] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[34] Chris Bailey-Kellogg,et al. Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..
[35] Anne S De Groot,et al. Immunogenicity of protein therapeutics. , 2007, Trends in immunology.
[36] D E Banks,et al. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. , 1997, The Journal of clinical investigation.
[37] Chris Bailey-Kellogg,et al. Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.
[38] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[39] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[40] R. Dubridge,et al. The immunogenicity of humanized and fully human antibodies , 2010, mAbs.
[41] A. Sant,et al. Understanding the focused CD4 T cell response to antigen and pathogenic organisms , 2009, Immunologic research.
[42] E. Birney,et al. Pfam: the protein families database , 2013, Nucleic Acids Res..
[43] Bruce Randall Donald,et al. Protein Design Using Continuous Rotamers , 2012, PLoS Comput. Biol..
[44] J. Richardson,et al. The penultimate rotamer library , 2000, Proteins.
[45] P Argos,et al. Oligopeptide biases in protein sequences and their use in predicting protein coding regions in nucleotide sequences , 1988, Proteins.
[46] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[47] George Georgiou,et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.
[48] D. Baker,et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.
[49] Chris Bailey-Kellogg,et al. Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .
[50] D. Collen,et al. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency. , 1997, Circulation.